NeuroOne Medical Technologies Corporation (OTCQB: NMTC) today reported business highlights for the fiscal year ended December 31, 2017 and outlined plans for 2018.
Dave Rosa, CEO of NeuroOne stated, “In 2017, we made great progress in our efforts to develop and commercialize our patented thin film electrode technology. We believe that this technology can offer improved and unique diagnostic and therapeutic benefits for patients, physicians and the health care system once we have received the necessary regulatory clearance.”
- Completed reverse merger
- Up-listed to the OTCQB
- Raised over $1.8 million in private transactions
- Established physician advisory board
- Completed early feasibility testing for depth electrode and combination diagnostic/ablation depth electrode
- Filed two provisional patents with the U.S. Patent and Trade Office
2018 Key Objectives
- File patent application(s) based on the submitted 2017 provisional patents
- Complete pre-clinical study for NeuroOne’s diagnostic and diagnostic/ablation combination depth electrode
- Submit 510(k) application for cortical electrode in the second half of 2018
- Ramp up production and hire initial sales force representatives for cortical electrode
- Continue to strengthen physician advisory board where appropriate
Rosa concluded, “We are confident in our corporate strategy moving forward and are excited to have the support and guidance from our physician advisory board and other key advisors. We will provide updates on future company progress as appropriate.”
NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from Epilepsy, Parkinson’s Disease, Essential Tremors and other related neurological disorders that may improve patient outcomes and reduce procedural costs.
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the Company’s business strategy, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the technology. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. These forward‐looking statements are subject to a number of risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the SEC. These forward‐looking statements speak only as of the date of this presentation and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future.